| Literature DB >> 28034960 |
Attila Szebeni1, Katalin Szebeni1, Timothy P DiPeri1, Luke A Johnson1, Craig A Stockmeier2,3, Jessica D Crawford1, Michelle J Chandley4, Liza J Hernandez1, Katherine C Burgess1, Russell W Brown1, Gregory A Ordway5.
Abstract
Background: Pathology of white matter in brains of patients with major depressive disorder (MDD) is well-documented, but the cellular and molecular basis of this pathology are poorly understood.Entities:
Keywords: DNA; anhedonia; messenger RNA; oligodendrocyte; oxidative stress
Mesh:
Substances:
Year: 2017 PMID: 28034960 PMCID: PMC5412018 DOI: 10.1093/ijnp/pyw114
Source DB: PubMed Journal: Int J Neuropsychopharmacol ISSN: 1461-1457 Impact factor: 5.176
Subject Demographics
| Subject Code | Gender | pH | RIN | PMI | Smoker | Toxicology | Axis I Diagnosis | Suicide | Tissue | Assay |
|---|---|---|---|---|---|---|---|---|---|---|
| Normal control donors | ||||||||||
| 1 c | M | 6.47 | 7.3 | 17.0 | No | NDD | None | No | UF | Ox |
| 2 c | M | 6.49 | 6.9 | 23.0 | No,hx | Norpropoxyphene, propoxyphene, oxycodone | None | No | UF, BA10 | Ox, GE |
| 3 c | M | 6.28 | 6.4 | 17.0 | No | None | None | No | UF | GE |
| 4 c | M | 6.42 | 7.4 | 11.0 | No | NDD | None | No | UF, BA10 | Ox, GE |
| 5 c | M | 6.10 | 7.1 | 25.0 | No | Propoxyphene | None | No | UF, BA10 | Ox, GE |
| 6 c | M | 6.95 | 6.8 | 19.0 | No | NDD | None | No | UF, BA10 | Ox, GE |
| 8 c | M | 6.76 | 7.0 | 11.0 | No | NDD | None | No | UF | GE |
| 9 c | M | 6.72 | 6.7 | 16.0 | No | None | None | No | UF | GE |
| 10 c | M | 6.88 | 8.4 | 17.0 | Yes | NDD | None | No | UF, BA10 | Ox, GE |
| 11 c | M | 6.79 | 7.6 | 6.0 | No,hx | Lidocaine | None | No | UF, BA10 | Ox, GE |
| 12 c | M | 6.95 | 7.2 | 24.0 | Yes | None | None | No | UF | GE |
| 13 c | M | 6.80 | 7.1 | 17.0 | Yes | None | None | No | UF | GE |
| 14 c | M | 6.98 | 7.4 | 9.0 | Yes | NDD | None | No | BA10 | Ox, GE |
| 15 c | M | 6.78 | 7.7 | 21.0 | Yes | Ethanol | None | No | BA10 | GE |
| 16 c | F | 6.57 | N/A | 32.5 | No | NDD | None | No | BA10 | Ox |
| 18 c | M | 6.58 | N/A | 22.0 | No | NDD | None | No | BA10 | Ox |
| 19 c | F | 6.59 | N/A | 21.0 | Yes | Brompheniramine | None | No | BA10 | Ox |
| 20 c | M | 6.71 | N/A | 24.0 | No | Ethanol | None | No | BA10 | Ox |
| MEAN | 6.66 | 7.21 | 18.5 | |||||||
| SEM | 0.06 | 0.13 | 1.5 | |||||||
| Donors with Major Depressive Disorder | ||||||||||
| 1 d | M | 6.67 | 6.9 | 31.0 | No | Ethanol | MDD | Yes | UF, BA10 | Ox, GE |
| 2 d | M | 6.80 | 6.8 | 20.0 | Yes | Acetone | MDD | Yes | UF, BA10 | Ox, GE |
| 3 d | M | 6.48 | 5.8 | 18.0 | No | CO 83% | MDD | Yes | UF | GE |
| 4 d | M | 6.27 | 7.5 | 30.0 | Yes | CO 75% | MDD | Yes | UF, BA10 | Ox, GE |
| 5 d | M | 6.84 | 7.0 | 11.0 | No | EtOH | MDD | Yes | UF, BA10 | Ox, GE |
| 6 d | M | 6.26 | 7.5 | 17.0 | No | NDD | MDD | No | UF, BA10 | Ox, GE |
| 8 d | M | 6.70 | 6.7 | 20.0 | No | Diphenhydramine | MDD | Yes | UF | GE |
| 9 d | M | 6.23 | 7.0 | 21.0 | Hx | NDD | MDD | Yes | UF | GE |
| 10 d | M | 6.91 | 8.0 | 18.0 | Yes | NDD | MDD | Yes | UF, BA10 | Ox, GE |
| 11 d | M | 6.32 | 6.8 | 20.0 | No | Ethanol | MDD | Yes | UF, BA10 | Ox, GE |
| 12 d | M | 6.20 | 6.7 | 30.0 | Yes | Codeine | MDD | Yes | UF | GE |
| 13 d | M | 6.60 | 6.6 | 17.0 | No | NDD | MDD | Yes | UF | GE |
| 14 d | M | 6.24 | 6.7 | 19.2 | Yes | Chlorpheniramine | MDD | No | BA10 | Ox, GE |
| 15 d | M | 6.80 | 7.2 | 26.0 | Yes | Ethanol | MDD | Yes | BA10 | GE |
| 26 d | M | 6.50 | N/A | 14.0 | No | Tolnaftate, brucine | MDD | No | BA10 | Ox |
| 27 d | M | 6.67 | N/A | 26.0 | Yes | Sertraline, carbamazepine | MDD | No | BA10 | Ox |
| MEAN | 6.53 | 6.9 | 21.1 | |||||||
| SEM | 0.06 | 0.1 | 1.5 | |||||||
| Donors with Schizophrenia | ||||||||||
| 16 d | F | 5.74 | N/A | 18.0 | No | NDD | SCZ | No | BA10 | Ox |
| 17 d | M | 6.62 | N/A | 16.0 | Yes | NDD | SCZ | No | BA10 | Ox |
| 18 d | M | 6.77 | N/A | 16.0 | Yes | NDD | SCZ | No | BA10 | Ox |
| 19 d | F | 6.58 | N/A | 6.0 | Yes | Amoxapine, loxapine | SCZ | No | BA10 | Ox |
| 20 d | M | 6.78 | N/A | 10.0 | Yes | Ethanol | SCZ | Yes | BA10 | Ox |
| 21 d | M | 6.76 | N/A | 24.0 | Yes | NDD | SCZ | Yes | BA10 | Ox |
| 22 d | M | 6.71 | N/A | 19.0 | No | NDD | SCZ | Yes | BA10 | Ox |
| 23 d | M | 6.70 | N/A | 15.0 | Yes | Ethanol, cocaine, diphenydramine | SCZ | Yes | BA10 | Ox |
| 24 d | M | 6.70 | N/A | 24.0 | No | Olanzapine | SCZ | Yes | BA10 | Ox |
| 25 d | M | 6.55 | N/A | 12.2 | Yes | Olanzapine | SCZ | Yes | BA10 | Ox |
| MEAN | 6.59 | N/A | 16.7 | |||||||
| SEM | 0.08 | N/A | 1.7 | |||||||
RNA integrity number generated by the Agilent Bioanalyzer 2100.
Postmortem interval.
No drugs detectable.
History.
Uncinate fasciculus.
DNA oxidation assay.
Gene expression assay.
Not applicable to donors that were used for only DNA oxidation studies.
Schizophrenia.
Figure 1.Measurement of 8-hydroxydeoxyguanosine (8OHdG) immunoreactivity in homogenates of BA10 white matter from psychiatrically normal control donors (CON, n=13), major depressive disorder donors (MDD; n=10) and schizophrenia donors (SCHZ; n=10). The two psychiatric groups include suicide and non-suicide causes of death in panel A. The same data appears in panel B with psychiatric groups divided according to cause of death, i.e. suicide (n=12 consisting of 6 MDD and 6 SCHZ donors) and non-suicide (n=8 consisting of 4 MDD and 4 SCHZ donors). P values for group comparisons that reached statistical significance are noted.
Figure 2.Expression levels of BER enzyme genes, PARP1 (panels A and B) and OGG1 (panels C and D) in laser captured oligodendrocytes (panels A and C) and astrocytes (panels B and D) from BA10 white matter of psychiatrically normal control donors (white bars) and MDD donors (black bars). P values for group comparisons that reached statistical significance are noted.
Figure 3.Relationship between expression levels of PARP1 and OGG1 in white matter glia in normal control (panels A and C) and MDD (panels B and D) donors. Each graph shows gene expression levels in cells laser captured from both uncinated fasciculus and BA10 white matter for each group of subjects. Pearson correlations and p values are shown.
Figure 4.The effect of repeated exposure to social defeat stress plus unpredictable stress on sucrose preference in the two-bottle choice task (A), time spent in the interaction zone (B), and DNA oxidation levels (C) measured in prefrontal cortical white and gray matter of rats. For each graph, white bars indicate handled control rats and black bars indicate stressed rats. Sucrose preference was measured over the last three days (day 8–10) of the stress paradigm (N=14 rats per group). Repeated measures ANOVA revealed a significant effect of stress on sucrose preference across the three days (p = 1x10-5). Interaction zone times were measured on the 11th day, 24 h after the last social defeat session (N=14 rats per group). DNA oxidation levels were measured two days after the last stressor (day 12) in 8 rats from each of the same two groups of rats used for the two-bottle choice task and interaction zone measurements. Statistically significant comparisons are shown above the bars for panels B and C.